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Abstract
Background: Erythropoietin possesses cellular protection properties. The aim of the present
study was to test the hypothesis that in situ expression of recombinant human erythropoietin
(rhEPO) would improve tissue repair in rat after myocardial infarction (MI).
Methods and results: RhEPO-producing cardiac fibroblasts were generated ex vivo by
transduction with retroviral vector. The anti-apoptotic effect of rhEPO-producing fibroblasts was
evaluated by co-culture with rat neonatal cardiomyocytes exposed to H2O2-induced oxidative
stress. Annexin V/PI assay and DAPI staining showed that compared with control, rhEPO forced
expression markedly attenuated apoptosis and improved survival of cultured cardiomyocytes. To
test the effect of rhEPO on the infarcted myocardium, Sprague-Dawley rats were subjected to
permanent coronary artery occlusion, and rhEPO-producing fibroblasts, non-transduced
fibroblasts, or saline, were injected into the scar tissue seven days after infarction. One month later,
immunostaining identified rhEPO expression in the implanted engineered cells but not in controls.
Compared with non-transduced fibroblasts or saline injection, implanted rhEPO-producing
fibroblasts promoted vascularization in the scar, and prevented cell apoptosis. By two-dimensional
echocardiography and postmortem morphometry, transplanted EPO-engineered fibroblasts did
not prevent left ventricular (LV) dysfunction and adverse LV remodeling 5 and 9 weeks after MI.
Conclusion: In situ expression of rhEPO enhances vascularization and reduces cell apoptosis in
the infarcted myocardium. However, local EPO therapy is insufficient for functional improvement
after MI in rat.
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Erythropoietin (EPO), a hematopoietic cytokine, has been
shown to possess cardioprotective characteristics that can
minimize ischemic injury and improve myocardial viabil-
ity and function [1]. Systemic administration of recom-
binant human EPO (rhEPO) before or after myocardial
ischemia reduces infarct size and improves cardiac func-
tion [2,3]. The beneficial effects of EPO are mediated by
apoptosis inhibition, driven by Akt/phosphoinositide3-
kinase signaling [4,5], and neovascularization by stimula-
tion of endothelial progenitor cells [6,7]. However, sys-
temic administration of EPO to patients with coronary
artery disease could lead to adverse effects, such as high
viscocity, impaired tissue perfusion, high blood pressure
and an increased incidence of thrombosis [8,9]. Hemat-
ocrit elevation has been linked to excess mortality in
patients with ischemic heart disease [10,11]. Over-expres-
sion of rhEPO in transgenic mice resulted in cardiac dys-
function and reduced life span [12,13]. Overall, the
potential adverse effects associated with systemic EPO
administration suggest that alternative approaches are
needed.
A particularly beneficial approach would be a strategy that
could provide local rhEPO delivery into the infarcted
heart. A recent study has suggested that cardiac fibroblasts
are critical effectors for erythropoietin-mediated pro-sur-
vival signaling and cardiac protection [14]. In the present
study, we aimed to test the hypothesis that cardiac fibrob-
lasts can be reprogrammed ex vivo to produce rhEPO, and
that re-implantation of the engineered cells into the inf-
arcted myocardium could promote tissue healing and
repair.
Materials and methods
The study was performed in accordance with the Animal
Care and Use Committee guidelines of the Tel Aviv Uni-
versity, Tel Aviv, Israel, which conforms to the policies of
the American Heart Association.
Retroviral vector
Amphotrophic rhEPO (pBabe-EPO) retrovirus-containing
packaging cell line PT67 was used for retroviral vector pro-
duction [15]. Twenty-four hour filtered (0.45 μm) culture
virus-containing supernants were stored at -80°C for
future experiments. The presence and titer of rhEPO-retro-
viral vector were assayed by infecting BALB/3T3 (ATCC
number CCL-163) mouse fibroblast cell line and a CFU
(colony-forming unit) number determination.
Isolation of cardiac cells
Cardiac fibroblasts and cardiomyocytes were isolated
from 1–2 day old neonatal Sprague-Dawley rats (Harlan
Lab, Jerusalem, Israel) as previously described [16]. We
used a 30 minute pre-plating procedure to obtain cardiac
fibroblasts and to reduce the number of non-myocyte
cells in cardiomyocyte culture. The purity of obtained car-
diac fibroblast culture was confirmed microscopically by
characteristic cell morphology. Neonatal rat cardiomyo-
cytes were used for oxidative stress studies and cardiac
fibroblasts were used for transduction and transplanta-
tion studies.
Cell transduction
BALB/3T3 (ATCC number CCL-163) mouse fibroblast cell
line and isolated cardiac fibroblasts were used for trans-
duction experiments. RhEPO retrovirus-containing super-
nants were first incubated at room temperature with a
Superfect cationic transfection reagent (QIAGEN, West-
burg Ltd., Be'er-Sheva, Israel) to a final concentration of
10 μg/ml for 15 minutes [17]. Finally, the viral stock was
added to 70–80% confluent BALB/3T3 or cardiac fibrob-
last culture. After 24 h incubation at 37°C, puromycin
selection was applied (2.5 μg/ml). Transduction efficiency
was approximately 80%, as evaluated qualitatively by rel-
ative confluence determination (before and after puromy-
cin selection). Twenty-four hour culture supernants were
collected for EPO assessment. Supernants were stored at -
20°C for future experiments.
Assessment of EPO production and activity
RhEPO protein levels
The presence of rhEPO in transduced culture supernants
was analyzed by a commercial ELISA kit (R&D Systems,
Minneapolis, MN, USA). EPO concentration was normal-
ized to 106 cells for 24 h.
RhEPO biologic activity (TF-1 cell proliferation assay)
EPO biological activity was analyzed using the EPO-sensi-
tive human erythroleukemia cell line TF-1, in which pro-
liferation and metabolic activity is EPO-dependent [18].
TF-1 cells were seeded in 96-well plates (1 × 105 cell per
well in 100 μl of RPMI medium). A total of 100 μl of pre-
viously collected culture supernants, controls or standards
(0.01 to 5 IU/ml rhEPO; Eprex, Beerse, Belgium) were
added to each well. On day 5 of the experiment, TF-1 rel-
ative cell number was analyzed using colorimetric XTT
assay kit (Biological Industries, Beth Haemek, Israel). The
XTT assay is based on the ability of metabolically active
(live) cells to reduce tetrazolium salt (XTT) to orange-
colored compounds of formazan. EPO activity in supern-
ants from rhEPO-transduced fibroblast culture was calcu-
lated from XTT rhEPO standard calibration curve. EPO
relative biological activity was determined by EPO activity
level/EPO protein level (measured by ELISA) ratio. This
amount-normalized protein ratio was used for compari-
son of biological activity between expressed EPO (pro-
duced from transduced cells) and recombinant protein.Page 2 of 11
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After 6 days in culture, isolated rat neonatal cardiomyo-
cytes were pretreated with supernants collected from
rhEPO-transduced or non-transduced (for control) car-
diac fibroblasts for 24 h, after which H2O2 was directly
added to culture medium to a 150 μM final concentration
for 60 minutes, and the degree of apoptosis was tested.
Apoptosis assays
Annexin V/propidium iodide assay
Apoptosis assessment was performed using Annexin-V-
FLUOS (fluorescein)/propidium iodide (PI) staining kit
(Roche Diagnostics GmbH, Penzberg, Germany). The
samples were prepared according to the manufacturer's
instructions and were analyzed by flow cytometry.
Annexin-V-positive and PI-negative cells were scored as
apoptotic cells.
DAPI staining
Apoptotic morphological changes were evaluated by
DAPI (4',6'-diamidino-2-phenylindole) staining. After
oxidative stress induction, cells were gently washed with
phosphate-buffered saline (PBS) and fixed with cold
methanol for 10 minutes. The plates were washed twice
with PBS and incubated for 5 minutes with 300 μM DAPI
(catalogue number D-3571, Molecular Probes, Eugene,
Oregon, USA) at 37°C. Finally, the cells were washed
three times with PBS and examined by fluorescence
microscopy. Apoptotic cells were identified by condensa-
tion and fragmentation of the nuclei, and were quantified
by counting a total of 200 nuclei from each well and cal-
culating the percentage of apoptotic nuclei.
Rat model of acute myocardial infarction
Male Sprague-Dawley rats (approximately 250 g; Harlan
Lab, Jerusalem, Israel) were subjected to acute myocardial
infarction (AMI) induction by permanent coronary artery
occlusion, as previously described [19].
Cell transplantation
RhEPO-transduced and non-transduced fibroblast trans-
plantations were performed 7 days after AMI. After 10
days in culture (7 days after transduction, 3 passages), car-
diac fibroblasts were prepared for transplantation by
trypsinization with 0.25% Trypsin-EDTA solution for 1
minute at 37°C. The rhEPO expression level in prepared
cells was 7.0 ± 0.23 mIU/24 h/106 cells. Following centrif-
ugation (1,500 rpm, 10 minutes at room temperature) the
cells were re-suspended in saline. The final cell density for
implantation was 1 × 106 cells/100 μl. Rats were anesthe-
tized and the chest was opened under sterile conditions.
The infarcted area was identified visually by the surface
scar and wall motion akinesis. Rats were randomized and
selected either for injection of 1 × 106 rhEPO-transduced
cells, 1 × 106 non-transduced cells, or saline (n = 5 in each
group). All injections were made into the center of the
scar. After the injection, the air was expelled from the
chest, and the surgical incision was sutured closed
[19,20].
Echocardiography
Transthoracic echocardiography was performed on all
animals before transplantation (baseline echocardio-
gram) and 5 and 9 weeks later (4 and 8 weeks post-trans-
plantation, respectively). Echocardiograms were
performed with a commercially available echocardiogra-
phy system (Sonos 7500; Philips) equipped with 12.5
MHz phased-array transducer (Hewlett-Packard, Andover,
MA, USA) as previously described [21,22]. All measure-
ments were averaged over three consecutive cardiac cycles
and were performed by an experienced technician who
was blinded to the treatment group.
Hematocrit measurements
For evaluation of possible systemic effects of rhEPO pro-
duced from transplanted cells, hematocrit measurements
were performed before or 1 and 4 weeks after transplanta-
tion.
Immunohistochemical analysis
Four weeks after transplantation, hearts were arrested with
15% KCl, perfused with formaldehyde 4% (15 mmHg)
for 20 minutes, sectioned into 3–4 transverse slices, and
parallel to the atrioventricular ring. Each slice was fixed
with 10% buffered formalin, embedded in paraffin, and
sectioned into 5 μm slices. Serial sections were stained
with the following agents: anti-α-smooth muscle actin
monoclonal antibodies (Sigma-Aldrich, Rehovot, Israel)
to localize pericytes and arterioles for neovascularization
evaluation; anti-active caspase-3 polyclonal antibodies
(Biocare Medical, Walnut Creek, CA, USA) for apoptosis
detection; anti-rhEPO monoclonal antibodies (R&D Sys-
tems, Minneapolis, MN, USA) to localize rhEPO produc-
tion and distribution; lectin (Bandeirea simplicifolia
agglutinin BS-1; Sigma-Aldrich, Rehovot, Israel) to local-
ize vascular endothelium; and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) using
Apoptag Peroxidase In situ Apoptosis Kit (S7101, Chemi-
con, Temecula, CA, USA) to assess apoptosis. The degree
of neovascularization was evaluated by capillary blood
vessel and arteriole counts in the infarct border zone (at
least three different fields were counted). Apoptosis eval-
uation was made by active caspase-3 or TUNEL-positive
cell counts in the infarct border zone (at least five different
fields were counted). Co-staining was made with haema-
toxylin or methyl green for TUNEL.
Morphometric analysis
After perfusion pressure fixation (15 mmHg), slides
stained with Masson's trichrome (Dexmore, Israel) werePage 3 of 11
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pometric analysis, as previously described [23]. The fol-
lowing parameters were measured: LV maximal diameter
(mm), average wall thickness (mm; averaged from three
measurements of septum thickness), average scar thick-
ness (mm; averaged from three measurements of scar
thickness), relative scar thickness (average scar thickness/
average wall thickness), LV muscle area (mm2; including
the septum), LV cavity area (mm2), whole LV area (mm2),
infarct expansion index ([LV cavity area/Whole LV area]/
Relative scar thickness), epicardial scar length (mm), and
endocardial scar length (mm).
Statistical analysis
All values are given as means ± standard error of the mean
(SEM) from at least three independent experiments.
RhEPO activity results were compared with Student's t-test
for unpaired data. Cardiomyocyte or general cell apopto-
sis results and blood vessel counts were compared by one-
way ANOVA with Bonferroni post test.
In the echocardiography study, because each animal was
used as its own control, changes between baseline and 4
weeks in the control and treated groups were assessed
with paired t-tests. Comparisons of the changes from
baseline to 5 and 9 weeks in the control and treatment
groups were made with repeated-measure two-way
ANOVA. The ANOVA model included control versus
treatment and baseline versus 5 and 9 weeks as factors, as
well as the interaction between the two factors. GraphPad
Prism version 4.00 for Windows (GraphPad Software, San
Diego, California, USA) was used for analysis.
Comparison of morphometry parameters and hematocrit
measurements among treatment groups was analyzed by
one-way ANOVA with Bonferroni post test. All tests were
performed using GraphPad Prism Version 4.0. P < 0.05
was considered statistically significant.
Results
Ex vivo retroviral gene transfer and rhEPO expression
To test retroviral ability for stable expression of biologi-
cally active rhEPO, the initial transduction experiments
were carried out using BALB/3T3 mouse fibroblast cell
line. Table 1 describes the activity of EPO produced from
transduced cells. ELISA was used to evaluate EPO concen-
trations, and its biological activity was determined by pro-
liferation of the EPO-sensitive human erythroleukemia
cell line TF-1. The activity induced by recombinant
human EPO (Eprex) was used as a standard in this assay.
Produced EPO protein was found to be 35 times more
biologically active than recombinant protein (Eprex;
Table 1, p = 0.0006). The rhEPO production level in trans-
duced cultures was 11.5 ± 0.8 mIU/24 h/106 cells.
To generate viable cardiac cell culture producing rhEPO
for subsequent transplantation, we used rat neonatal car-
diac fibroblasts. EPO activity parameters of transduced
cardiac fibroblasts are presented in Table 1. The produced
protein was found to be 12 times more active than recom-
binant protein (Eprex; p = 0.03). The rhEPO production
level in transduced cells was 14.2 ± 3.1 mIU/24 h/106
cells.
Anti-apoptotic effect of EPO in isolated cardiomyocytes
The rate of apoptosis was significantly lower in cultured
cardiomyocytes treated with supernants derived from
rhEPO-tranduced fibroblasts. To determine the protective
effect of rhEPO produced from genetically modified car-
diac fibroblasts on cardiomyocyte apoptosis, we used an
H2O2-induced oxidative stress model [24]. Isolated rat
neonatal cardiomyocytes were treated with 150 μM H2O2
for 60 minutes, with or without 24 h preconditioning
with supernants containing rhEPO (12 mIU/ml) from
transduced cardiac fibroblasts. The degree of apoptosis
was assayed by Annexin V/PI staining and morphologi-
cally evaluated using a DAPI nuclear stain. FACS analysis
of Annexin V/PI staining showed that the percentage of
apoptotic cells was significantly lower in cardiomyocytes
pretreated with rhEPO-containing supernants compared
with control (Figure 1A): 17.8 ± 2.3% versus 32.1 ± 3.7%
apoptotic cells (p < 0.05).
Morphological changes in cells that were exposed to oxi-
dative stress were evaluated after DAPI staining. Apoptotic
nuclei counts showed a significant reduction in cell death
in cells treated with rhEPO-containing supernants, com-
Table 1: EPO biological activity in vitro
Culture EPO ELISA (mIU/ml) EPO activity assay (TF-1) (mIU/ml) Activity ratio (activity/protein)
Mock BALB/3T3 0 0 -
Transduced BALB/3T3 10.74 ± 0.78 373.3 ± 37.12* ×35
Mock neonatal fibroblasts 0 0 -
Transduced neonatal fibroblasts 51.24 ± 11.17 576.7 ± 186.7* ×12
RhEPO protein levels: the presence of rhEPO in transduced culture supernants was analyzed by a commercial ELISA kit. RhEPO biologic activity 
(TF-1 cell proliferation assay): EPO biological activity was analyzed using the EPO-sensitive human erythroleukemia cell line TF-1, in which 
proliferation and metabolic activity is EPO-dependent. *Significantly more active than rhEPO standard (Eprex), p < 0.05.Page 4 of 11
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RhEPO inhibits H2O2-induced apoptosis in isolated cardiomyocytesFigure 1
RhEPO inhibits H2O2-induced apoptosis in isolated cardiomyocytes. Neonatal rat cardiomyocytes were treated with 
PBS as a control or with H2O2 (150 μM) for 60 minutes in the 24 h presence or absence of rhEPO produced from transduced 
fibroblasts (12 mIU/ml). (A) Annexin V/PI staining: (a) Representative density profile (percentage of cells in each quadrant is 
indicated); (b) Quantitative analysis, showing that EPO attenuated cardiomyocyte apoptosis. (B) DAPI staining: (a) representa-
tive photomicrographs (arrows show apoptotic cardiomyocyte nuclei (chromatin condensation and nuclei fragmentation); (b) 
quantitative analysis, as represented by relative apoptotic nuclei counts.
Table 2: Serial hematocrit measurements in rats after MI, showing that EPO-transduced cell injection does not increase systemic 
hematocrit levels
Treatment time Saline (n = 9) EPO-transduced cells (n = 9) Non-transduced cells (n = 9)
Baseline (before injection; %) 47.5 ± 0.3 47.2 ± 0.2 47.2 ± 0.1
1 week post-injection (%) 47.4 ± 0.2 47.0 ± 0.1 47.39 ± 0.2
4 weeks post-injection (%) 47.4 ± 0.18 46.8 ± 0.2 47.15 ± 0.2
p = 1.00.
Fibrogenesis & Tissue Repair 2008, 1:7 http://www.fibrogenesis.com/content/1/1/7pared to untreated cells: 13.5 ± 0.6% versus 19.0 ± 0.7%,
p < 0.001 (Figure 1B).
In situ expression of erythropoietin promotes 
cytoprotection and vascularization
There was no difference among the groups in the levels of
hematocrit at all time points (Table 2). Four weeks after
cell transplantation, heart tissue sections were stained
with anti-rhEPO monoclonal antibodies to detect rhEPO
expression from implanted cells. Human kidney tissue
was used as positive control (Figure 2A). RhEPO was
detected only in hearts treated with transduced cardiac
fibroblasts 5 weeks post MI (Figure 2B–D). The staining
was identified in all animals treated with transduced cells
(n = 5), towards the center of the infarct zone.
The degree of vascularization was evaluated by counting
capillary blood vessels in the infarct border zones using α-
smooth muscle actin and lectin stainings for vascular
endothelium localization. Compared with non-trans-
duced fibroblasts and saline, implanted rhEPO-producing
fibroblasts enhanced angiogenesis, as shown in both α-
smooth muscle actin (Figure 3A; 15.27 ± 0.37 versus 9.93
± 0.97 versus 9.57 ± 0.72 vessels/mm2, respectively, p <
0.05), and lectin stained sections (Figure 3B; 70.1 ± 8.5
versus 47.5 ± 5.9 versus 20.7 ± 3.6 vessels/mm2, respec-
tively, p < 0.05).
Apoptosis in infarcted hearts was detected by active cas-
pase-3 staining with polyclonal antibodies detecting only
the active (effector) form of caspase-3 (Figure 4A) [25,26].
Human tonsil tissue was used as a positive control (Figure
4A, a). RhEPO-transduced cell transplantation resulted in
a significant decrease in the number of active-caspase-3
positive cells (24 ± 6 versus 176 ± 20 versus 110 ± 27 cells
per mm2 in saline and non-transduced cell injections, p <
0.05; Figure 4C, a). The staining revealed mainly nuclear
localization of active caspase-3 (Figure 4A) [26]. Apopto-
sis was also evaluated by commercially available TUNEL
kit (Figure 4B). Rat mammary gland tissue served as a pos-
itive control (Figure 4B, a). Similar to active caspase-3
staining, TUNEL staining showed that rhEPO-transduced
Photomicrographs of heart sections, immunostained with anti-human e ythropoietin antibodies (brown), 4 weeks after cell ransplant ionFigu e 2
Photomicrographs of heart sections, immunostained 
with anti-human erythropoietin antibodies (brown), 
4 weeks after cell transplantation.(A) Human kidney 
positive control. (B) saline-injected heart. (C) Non-trans-
duced fibroblast-transplanted heart. (D) RhEPO in trans-
duced fibroblast-transplanted heart (infarct zone). Arrows 
show rhEPO expression.
Four weeks after cell transplantation, rhEPO expression pro-motes n o-angiogenesis in vivoigure 3
Four weeks after cell transplantation, rhEPO expres-
sion promotes neo-angiogenesis in vivo. (A) α-Smooth 
muscle actin staining (brown) in infarcted hearts (infarct bor-
der zones). Arrows show stained blood vessels. (a) Saline 
injection; (b) non-transduced cell injection; (c) rhEPO-trans-
duced cell injection; (d) quantitative analysis. (B) Lectin (BS-
1) staining (brown) in infarcted hearts (infarct border zones). 
Arrows show stained blood vessels. (a) Saline injection; (b) 
non-transduced cell injection; (c) rhEPO-transduced cell 
injection; (d) quantitative analysis.Page 6 of 11
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the number of apoptotic cells (118 ± 6 versus 182 ± 12
versus 157 ± 10 cells per mm2 in saline and non-trans-
duced cell injections, p < 0.05; Figure 4C, b). These results
suggest that local rhEPO expression prevented cardiac cell
apoptosis in vivo.
EPO-transduced cell injection did not improve LV 
remodeling and function
To examine potential cardioprotective effects of rhEPO-
producing fibroblasts in vivo, we used a rat model of AMI,
which resulted in progressive LV remodeling and dysfunc-
tion [19]. Overall, 45 rats were included in the final trans-
plantation study. Rats were randomized into three
treatment groups (n = 15 in each group): transduced
rhEPO-producing cells, non-transduced cells, and saline
injection. Ten animals from each group (five additional
animals in each group were sacrificed one month after
transplantation for immunohistochemical examination)
were assessed with echocardiography.
Serial echocardiography tests showed that EPO-trans-
duced and non-transduced cell injection did not reduce
LV remodeling and dysfunction 5 and 9 weeks post MI
(Table 3). At 5 weeks, there was a trend towards more scar
thinning in the EPO-treated group (anterior wall diastolic
thickness, p = 0.07; LV end diastolic dimension, p = 0.08).
Morhpometric analysis of the infarcted hearts showed
that EPO-transduced cell injection also fails to prevent inf-
arct expansion and scar thinning (Table 4). For major
parameters (average scar thickness, LV cavity area, whole
LV area and expansion index), EPO-transduced cells
showed significant adverse remodeling compared to non-
transduced cells with a magnitude similar to saline-treated
animals. Furthermore, non-transduced cell injection
attenuated infarct expansion and preserved LV area, com-
pared to saline-treated animals.
Discussion
To the best of our knowledge, the present study is the first
to use reprogrammed cardiac fibroblasts encoding the
rhEPO gene to repair infarcted myocardium in situ. In pre-
vious experiments, rhEPO was delivered systemically
prior to, at different time points and immediately after
ischemia/reperfusion or cardiomyopathy induction [27-
30]. In our study, rhEPO produced from genetically mod-
ified cardiac fibroblasts exhibited a strong anti-apoptotic
effect in vitro, promoted angiogenesis and attenuated
apoptosis in the infarcted tissue. However, despite posi-
tive in vitro results and cytoprotection of EPO-transduced
cells in the infarcted hearts, restoration of LV function was
not observed, and there was a trend to more adverse
remodeling.
Four weeks after cell transplantation, rhEPO expression attenuat s c rdiac cell apo tosis in vivoigure 4
Four weeks after cell transplantation, rhEPO expres-
sion attenuates cardiac cell apoptosis in vivo. (A) Rep-
resentative photomicrographs of active caspase-3 staining 
(brown) in infarcted hearts (infarct border zone). Arrows 
show nuclear active caspase-3 staining. (a) Human tonsil tis-
sue (positive control); (b) saline injection; (c) non-transduced 
cell injection; (d) rhEPO-transduced cell injection. (B) Rep-
resentative photomicrographs of TUNEL staining (brown) in 
infarcted hearts (infarct border zone). (a) Rat mammary 
gland tissue (positive control); (b) saline injection; (c) non-
transduced cell injection; (d) rhEPO-transduced cell injection. 
(C) Quantitative analysis of apoptosis in infarcted hearts. (a) 
active caspase-3 staining; (b) TUNEL.Page 7 of 11
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dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI
EPO-transduced cells (n = 10) Non-transduced cells (n = 9) Saline (n = 9) p†
5-week follow-up
Heart rate 0.17
Baseline 308.8 ± 12.6 273.8 ± 11.7 273.0 ± 11.6
5 weeks 252.7 ± 9.5 252.5 ± 14.0 262.8 ± 13.5
p* 0.0068 0.32 0.55
AW d (cm) 0.07
Baseline 0.13 ± 0.01 0.17 ± 0.007 0.13 ± 0.01
5 weeks 0.09 ± 0.006 0.10 ± 0.01 0.10 ± 0.01
p* 0.006 0.0002 0.04
LVEDD 0.08
Baseline 0.76 ± 0.02 0.72 ± 0.02 0.82 ± 0.02
5 weeks 1.06 ± 0.02 0.98 ± 0.03 1.00 ± 0.03
p* <0.0001 <0.0001 0.0009
LVESD 0.22
Baseline 0.60 ± 0.03 0.56 ± 0.02 0.64 ± 0.03
5 weeks 0.88 ± 0.03 0.81 ± 0.04 0.80 ± 0.04
p* <0.0001 <0.0001 <0.0001
LVEDA 0.34
Baseline 0.39 ± 0.03 0.35 ± 0.01 0.43 ± 0.02
5 weeks 0.73 ± 0.04 0.65 ± 0.04 0.67 ± 0.05
p* <0.0001 <0.0001 0.0011
LVESA 0.36
Baseline 0.24 ± 0.02 0.21 ± 0.01 0.26 ± 0.02
5 weeks 0.52 ± 0.04 0.42 ± 0.04 0.44 ± 0.05
p* <0.0001 <0.0001 0.0004
FS (%) 0.99
Baseline 20.6 ± 2.9 22.3 ± 1.7 25.07 ± 2.2
5 weeks 16.2 ± 1.4 17.8 ± 1.6 20.96 ± 2.0
p* 0.14 0.008 0.002
9-week follow-up
Heart rate 0.28
Baseline 303.2 ± 12.7 274.4 ± 13.3 273.0 ± 11.6
9 weeks 242.0 ± 6.3 235.5 ± 12.2 246.2 ± 7.7
p* 0.04 0.12 0.0014
AW d (cm) 0.19
Baseline 0.13 ± 0.01 0.17 ± 0.007 0.13 ± 0.01
9 weeks 0.09 ± 0.01 0.12 ± 0.01 0.11 ± 0.01
p* 0.03 0.0002 0.3
LVEDD 0.22
Baseline 0.76 ± 0.02 0.72 ± 0.02 0.82 ± 0.02
9 weeks 1.11 ± 0.04 1.03 ± 0.03 1.05 ± 0.03
p* <0.0001 <0.0001 0.0003
LVESD 0.3
Baseline 0.60 ± 0.03 0.56 ± 0.02 0.64 ± 0.03
9 weeks 0.95 ± 0.05 0.84 ± 0.04 0.86 ± 0.05
p* <0.0001 <0.0001 <0.0001
LVEDA 0.42
Baseline 0.39 ± 0.03 0.35 ± 0.01 0.43 ± 0.02Page 8 of 11
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the infarcted heart. Although not an 'ideal' source for
transplantation (due to lack of contractility and so on),
fibroblasts, constituting the major cell population of the
myocardium, can be easily obtained from clinically acces-
sible sites, expanded in vitro without significant limita-
tion, and, unlike cardiomyocytes, can be transduced
highly efficiently by retroviral EPO-based gene transfer.
Our findings concur with other studies that show a lack of
functional improvement following EPO treatment despite
positive cellular effects (apoptosis inhibition and angio-
9 weeks 0.83 ± 0.06 0.71 ± 0.05 0.74 ± 0.06
p* <0.0001 <0.0001 0.0006
LVESA 0.37
Baseline 0.24 ± 0.02 0.21 ± 0.01 0.26 ± 0.02
9 weeks 0.61 ± 0.06 0.48 ± 0.05 0.51 ± 0.06
p* 0.0001 0.0001 0.0003
FS (%) 0.09
Baseline 20.6 ± 2.9 22.3 ± 1.72 25.1 ± 2.2
9 weeks 14.3 ± 1.8 18.7 ± 1.73 19.8 ± 2.4
p* 0.05 0.02 0.0008
AW d, anterior wall diastolic thickness; LVEDD, LV end diastolic dimension; LVESD, LV end systolic dimension; LVEDA, LV end diastolic area; 
LVESA, LV end systolic area; FS, LV fractional shortening [(LVIDd – LVIDs)/LVIDd] × 100. Values are mean ± SEM; p*, p-values derived from paired 
comparisons between baseline and 5/9 week measurements; p†, p-values for the differences between groups over time (two-way repeated-
measures ANOVA, p-value for interaction).
Table 3: Comparison of LV remodeling and function between EPO-transduced, non-transduced cell or saline injections by two-
dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI (Continued)
Table 4: Comparison of LV remodeling by postmortem morphometry, 9 weeks after MI
EPO-transduced cells (n = 10) Non-transduced cells (n = 9) Saline (n = 9) p* ANOVA
LV maximal diameter (mm) 8.2 ± 0.4 6.2 ± 0. 31 8.1 ± 0.33 <0.0001
p (Bonferroni test) <0.001† <0.001‡ -
Average wall thickness (mm) 1.4 ± 0.05 1.2 ± 0.04 1.4 ± 0.03 0.003
p (Bonferroni test) <0.05† <0.05‡ -
Average scar thickness (mm) 0.62 ± 0.03 0.92 ± 0.04 1.0 ± 0.05 <0.0001
p (Bonferroni test) <0.001§ - -
Relative scar thickness 0.46 ± 0.05 0.59 ± 0.03 0.56 ± 0.05 0.22
p (Bonferroni test) - - -
Muscle area (mm2) 43 ± 1.4 43 ± 4.2 47 ± 2.3 0.55
p (Bonferroni test) - - -
LV cavity area (mm2) 57 ± 8.0 40 ± 4.9 65 ± 5.3 0.002
p (Bonferroni test) <0.05† <0.01‡ -
Whole LV area (mm2) 110 ± 7.5 77 ± 7.0 110 ± 7.0 <0.0001
p (Bonferroni test) < 0.001† < 0.001‡ -
Expansion index 1.1 ± 0.08 0.89 ± 0.05 1.2 ± 0.13 0.04
p (Bonferroni test) - <0.05‡ -
Epicardial scar length (mm) 7.2 ± 1.2 6.5 ± 1.2 8.1 ± 1.6 0.68
p (Bonferroni test) - - -
Endocardial scar length (mm) 7.3 ± 1.6 6.2 ± 1.2 6.6 ± 1.0 0.65
p (Bonferroni test) - - -
Values are means ± SEM. p (Bonferroni test), p-values from Bonferroni multiple comparison test; p*, p-values for the differences between groups 
(one-way ANOVA). †Versus non-transduced cells; ‡versus saline; §versus saline and non-transduced cells.Page 9 of 11
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with EPO analogue darbepoetin alfa [36].
The reason for the inconsistency between the cytoprotec-
tive effect of EPO in vitro and in situ versus the lack of func-
tional improvement in vivo is unclear. A possible
explanation is that an EPO therapeutic effect on LV
remodeling and function is mainly mediated by endothe-
lial progenitor cell recruitment, which is achieved by sys-
temic administration [34,37,38]. This notion is supported
by the positive correlation found between EPO plasma
levels and endothelial progenitor cell recruitment in an
observational study of patients after acute MI [39]. Thus,
local EPO therapy is insufficient for functional improve-
ment.
In addition, the lack of improvement could be related to
the timing of therapy. In most of the positive EPO studies
systemic cytokine administration was initiated before or
immediately after ischemia/reperfusion induction. We
used a more severely injured model with more clinically
relevant timing of cell delivery (1 week post MI). How-
ever, at this stage, EPO could be less effective due to a rel-
atively low cell apoptotic rate and the lack of stem cell
homing signals from the infarct [35].
Study limitations
Cell engraftment and survival was not quantified. Bromo-
deoxyuridine (BrdU) or other cellular markers were not
used to avoid interference with cell capacity to colonize
and proliferate. Such interference could cause a decrease
in the proposed EPO effect.
Retroviral transduction itself can potentially alter the phe-
notype of the transduced cells. However, the expression
profile of transduced cells did not exhibit any negative
effects when the transduced cell culture supernants were
added to cardiomyocyte culture in vitro.
In order to avoid possible systemic interference, we did
not apply an immunosuppression protocol. However,
EPO detection 1 month after cell transplantation suggests
that immune response, if evoked, is limited in magnitude.
The EPO tissue level could not be quantified due to tech-
nical constraints for detection of predicted low levels of
the protein.
Conclusion
In situ expression of rhEPO by genetically engineered car-
diac fibroblasts exerts cytoprotective and pro-angiogenic
effects. However, these favorable effects were not trans-
lated into functional improvement after MI. The results
suggest that for successful local EPO-based therapy, sev-
eral improvements should be made to determine the opti-
mal cell type for gene delivery, the most effective
recombinant viral vector, myocardial EPO response and,
notably, an accurate therapeutic window for cell and gene
transfer.
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